EU OKs Bivalent COVID-19 Vaccines From Pfizer/BioNTech & Moderna
The European Commission will shortly issue marketing authorizations for bivalent versions of Comirnaty and Spikevax targeting the Omicron BA.1 subvariant, after the European Medicines Agency recommended their approval for EU-wide use. Bivalent Spikevax has also been provisionally approved in Australia.
You may also be interested in...
How do you send 90,000 employees home and still bring a COVID-19 vaccine to market in record time? Pfizer showed the way and at a recent virtual event, senior vice-president Robert Brown revealed how the "secret sauce" of digitalization continues to help cut medical legal review times, crunch clinical trial duration and reduce service interruptions.
Coronavirus Notebook: UK OKs Second Bivalent Vaccine, European Companies Warn On Joint Vaccine Procurement Plans
The Swiss medicines regulator has approved the bivalent version of Spikevax and given the green light to use of the Novavax COVID-19 vaccine in younger people.
As regulators continue to process and approve applications for new kinds of COVID-19 booster vaccines, evidence is still awaited on the real-world benefits conferred by the latest variant-adapted products. The European Medicines Agency and the European Centre for Disease Prevention and Control plan to issue a joint statement on the use of adapted vaccines next week, and the EMA has OKd a booster version of the Novavax vaccine.